HDAC3
ENSG00000171720
Target class
Epigenetic regulator
Chromosome
5
Approved drugs
5
Clinical candidates (approved and in development)
12
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 12
- Chemical probe available
- Yes
- Target name
- HDAC3
- Gene name
- Histone deacetylase 3
- Gene symbol
- HDAC3
- Protein name
- Histone deacetylase 3 (HD3) (EC 3.5.1.98) (Protein deacetylase HDAC3) (EC 3.5.1.-) (Protein deacylase HDAC3) (EC 3.5.1.-) (RPD3-2) (SMAP45)
- RPD3
- HD3
- RPD3-2
- KDAC3
- Gene biotype
- Protein coding
- Gene family
- Histone deacetylases, class I|NCoR/SMRT transcriptional repression complex subunits
- Target class
- Epigenetic regulator
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 114.92
- Tissue specificity (Gini)
- 0.25
- Tissue specificity (tau)
- 0.545
- KEGG gene identifiers
- hsa:8841
- Protein interaction confidence
- 0.819875
- Protein interaction partners
- 112
- R-HSA-193670
- R-HSA-1989781
- R-HSA-2122947
- R-HSA-2151201
- R-HSA-2644606
- R-HSA-2894862
- R-HSA-3214815
- R-HSA-350054
- R-HSA-381340
- R-HSA-390471
- R-HSA-400206
- R-HSA-5617472
- R-HSA-8940973
- R-HSA-8943724
- R-HSA-9022537
- R-HSA-9022692
- R-HSA-9029569
- R-HSA-9609690
- R-HSA-9701898
- R-HSA-9707564
- R-HSA-9707616
- R-HSA-9841922
- R-HSA-9931509
- R-HSA-9933387
- R-HSA-9976102
- End position
- 141636867
- Start position
- 141620778
- Chromosome
- 5
- Strand
- Reverse
- Nucleus . Chromosome . Cytoplasm . Cytoplasm, cytosol . Note=Colocalizes with XBP1 and AKT1 in the cytoplasm (PubMed:25190803). Predominantly expressed in the nucleus in the presence of CCAR2 (PubMed:21030595). .
- Cytosol
- Golgi apparatus
- Nucleoplasm
- PubMed 21030595
- PubMed 16569215
- PubMed 18417529
- PubMed 25190803
- Tissue specificity (tau)
- 0.544993
- Expression inequality (Gini)
- 0.249796
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 114.92
- Skin - Sun Exposed (Lower leg)
- 86.95
- Cervix - Endocervix
- 83.59
- Cells - Cultured fibroblasts
- 83.28
- Ovary
- 82.51
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes114.92
- Skin - Sun Exposed (Lower leg)86.95
- Cervix - Endocervix83.59
- Cells - Cultured fibroblasts83.28
- Ovary82.51
- Uterus81.06
- Skin - Not Sun Exposed (Suprapubic)79.92
- Brain - Cerebellar Hemisphere79.23
- Cervix - Ectocervix78.97
- Brain - Cerebellum78.9
- Thyroid77.47
- Adrenal Gland77.43
- Spleen77.14
- Fallopian Tube72.94
- Vagina72.51
- Nerve - Tibial70.35
- Pituitary68.61
- Bladder66.85
- Prostate66.02
- Esophagus - Mucosa65.23
- Artery - Aorta62.33
- Artery - Tibial60.3
- Esophagus - Gastroesophageal Junction59.16
- Colon - Sigmoid58.43
- Lung58.34
And 29 more, listed on the interactive page.
- GO:0000122
- GO:0000132
- GO:0001934
- GO:0006325
- GO:0006476
- GO:0010832
- GO:0031647
- GO:0032008
- GO:0042307
- GO:0043066
- GO:0045892
- GO:0045944
- GO:0046329
- GO:0051225
- GO:0060633
- GO:0071498
- GO:0140861
- GO:0160020
- GO:0000118
- GO:0005634
- GO:0005654
- GO:0005694
- GO:0005737
- GO:0005829
- GO:0017053
- GO:0072686
- GO:0001222
- GO:0003682
- GO:0003714
- GO:0004407
- GO:0005515
- GO:0019899
- GO:0030332
- GO:0033558
- GO:0042826
- GO:0051059
- GO:0140229
- GO:0140297
- GO:0141221
- GO:0160008
- GO:0160009
- GO:0160010
- GO:0160216
regulation of catalytic activity
Studies
- biochemical: NVS_ENZ_hHDAC3, is one of one assay component(s) measured or calculated from the NVS_ENZ_hHDAC3 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (805)
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
- A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis
- A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
- A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
- A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
- A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)
- A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)
- A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
- A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer
- A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
- A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)
- A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
- A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer
- A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma
- A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.
- A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
- A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
- A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
- A Panobinostat Presurgery
Drugs (14)
- Abexinostat Histone deacetylase inhibitor
- Belinostat Histone deacetylase inhibitor
- CUDC-101 Histone deacetylase inhibitor
- Entinostat Histone deacetylase inhibitor
- Fimepinostat Histone deacetylase inhibitor
- Givinostat Histone deacetylase inhibitor
- Givinostat hydrochloride Histone deacetylase inhibitor
- Mocetinostat Histone deacetylase 3 inhibitor
- Panobinostat Histone deacetylase inhibitor
- Panobinostat lactate Histone deacetylase inhibitor
- Quisinostat Histone deacetylase inhibitor
- Romidepsin Histone deacetylase inhibitor
- Tacedinaline Histone deacetylase inhibitor
- Vorinostat Histone deacetylase 3 inhibitor